Arcus Biosciences Files 8-K
Ticker: RCUS · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1724521
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Arcus filed an 8-K, something happened, details TBD.
AI Summary
Arcus Biosciences, Inc. filed an 8-K on October 6, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event itself, only the standard reporting information for a current report.
Why It Matters
This filing indicates a material event has occurred that Arcus Biosciences is legally required to report to the SEC, though the specifics are not detailed in this initial report.
Risk Assessment
Risk Level: low — The filing itself is routine and does not disclose any negative or positive financial or operational information.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
FAQ
What specific event triggered this 8-K filing?
The provided text of the 8-K filing does not specify the exact event that triggered the report, only that it is being filed under 'Other Events'.
When was this 8-K filing submitted?
The filing was submitted on October 6, 2025.
What is the principal executive office address for Arcus Biosciences?
The principal executive offices are located at 3928 Point Eden Way, Hayward, California 94545.
What is the IRS Employer Identification Number for Arcus Biosciences?
The IRS Employer Identification Number is 47-3898435.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,424 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2025-10-06 10:02:38
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20251006.htm (8-K) — 71KB
- 0001724521-25-000107.txt ( ) — 187KB
- rcus-20251006.xsd (EX-101.SCH) — 2KB
- rcus-20251006_lab.xml (EX-101.LAB) — 21KB
- rcus-20251006_pre.xml (EX-101.PRE) — 12KB
- rcus-20251006_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. ARC-20 Updates On October 6, 2025, Arcus Biosciences, Inc. (the "Company") presented updated data from the monotherapy cohorts of ARC-20, a Phase 1/1b study evaluating different doses and combinations with casdatifan, and shared new research programs in immunology and inflammation. A copy of the presentation has been posted to the Investors & Media section of the Company's website. The presentation included updated data from four monotherapy cohorts evaluating casdatifan in patients with metastatic clear cell renal cell carcinoma, along with a pooled analysis comprising all patients from the four monotherapy cohorts. The efficacy-evaluable population included all eligible patients who received any study treatment and have at least one post-baseline efficacy assessment or who discontinued study treatment due to progressive disease or death, regardless of whether they had a scan. Below is a summary of the efficacy data as of the data cutoff date of August 15, 2025 (the "DCO"): 50 mg BID (n=31) 50 mg QD (n=28) 100mg QD (n=31) 150 mg QD (n=31) Pooled Analysis (n=121) Efficacy Median Follow-Up, months (range) 22.8 (14.4, 26.0) 19.7 (15.9, 21.3) 12.4 (6.3, 13.5) 14.4 (12.5, 15.5) 15.2 (6.3, 26.0) Median PFS, months [95% CI] 9.7 [5.3, NE] 19.2 [5.3, NE] NE [5.7, NE] 9.7 [2.7, NE] 12.2 [9.4, 20.6] 18-month PFS [95% CI] 41% [24, 58] 50% [30, 68] NE NE 43% [33, 53] 12-month PFS [95% CI] 44% [27, 61] 59% [39, 75] 60% [40,75] 40% [22, 56] 50% [41, 59] Confirmed ORR [95% CI] Complete Response, % (n) Partial Response, % (n) Stable Disease, % (n) Progressive Disease, % (n) 26% (12, 45) 0% (0) 26% (8) 55% (17) 19% (6) 36% (19, 56) 4% (1) 32% (9) 50% (14) 14% (4) 35% (19, 55) 0% (0) 35% (11) 48% (15) 16% (5) a 29% (14, 48) 0% (0) 29% (9) 45% (14) 26% (8) 31% (23, 40) 1% (1) 31% (37) 50% (60) 19% (23) ORR, including responses pending confirmation [95% CI] 26% [12, 45] 36% [19, 56] 42%* [25, 61] 29% [14, 48]
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: October 6, 2025 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)